A study of the effect of a platelet activating factor (PAF) receptor antagonist on antigen challenge of horses with chronic obstructive pulmonary disease.
Antigen challenge involving exposure to straw and mouldy hay for 7 h produced lung function changes and neutrophil recruitment to the lungs in horses with chronic obstructive pulmonary disease (COPD). During the challenge, an increase in radiolabelled neutrophils in the lungs occurred, together with increased respiratory rate and pleural pressure. The role of platelet activating factor (PAF) in antigen-induced neutrophil accumulation, and increased pleural pressure and respiratory rate was investigated by administering the PAF receptor antagonist WEB 2086 to asymptomatic COPD horses prior to antigen challenge. WEB 2086 (3 mg/kg i.v.) did not affect antigen-induced changes in either neutrophil accumulation or respiratory function. These results suggest that PAF may not be an important mediator of the response to antigen in equine COPD.
Marr
K A
KA
Department of Veterinary Basic Sciences, Royal Veterinary College, North Mymms, Hatfield, Herts, UK.
Fairbairn
S M
SM
Page
C P
CP
Lees
P
P
Cunningham
F M
FM
D000704:Analysis of Variance; D000818:Animals; D000941:Antigens / Q000633:toxicity; D001381:Azepines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D007553:Isotope Labeling; D007958:Leukocyte Count / Q000187:drug effects; D008173:Lung Diseases, Obstructive / Q000139:chemically induced / Q000188:drug therapy* / Q000662:veterinary; D008297:Male; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors*; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D014230:Triazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D000941:Antigens; D001381:Azepines; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D014230:Triazoles; C039351:platelet activating factor receptor; C052518:WEB 2086